
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is well positioned because its growth is increasingly coming from differentiated, high-margin products across all three segments, led by MIEBO, premium IOLs, and premium daily contact lenses. In Q3/26, revenue rose 7% y/y to $1,375MM and adjusted EBITDA jumped to $325MM, with margins expanding to 23.6% as gross margin reached 64.7%, while full-year 2026 adjusted EBITDA guidance was raised to $1.090–$1.140B. The company’s outlook is further supported by MIEBO’s 42% growth to $119M, premium IOLs up 75% CC, and strong contact lens momentum, suggesting durable share gains and improving operating leverage.
Bears say
Bausch & Lomb is facing a negative outlook because, despite 3Q26 revenue rising 7.3% YoY to $1,375M and management lifting FY2026 revenue guidance to $5,450-5,550M, the business is still weighed down by governance uncertainty and strategic ambiguity. The departure of CEO Brent Saunders, the appointment of Thomas Appio as interim CEO, and BHC’s roughly 87% ownership leave the company with overlapping control and no announced permanent leadership search, which clouds long-term capital allocation and separation plans. In addition, the FDA Warning Letter at the Tampa facility, ongoing remediation, and risks tied to competitive pressure, pricing, MIEBO execution, and contact lens demand all threaten margin durability and could limit the sustainability of recent growth.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Bausch + Lomb Corp (BLCO) Forecast
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares